Advertisement

Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults

  • Anita Tahlan
  • Neelam VarmaEmail author
  • Shano Naseem
  • Deepak Bansal
  • Jogeshwar Binota
  • Anil Sood
  • Man Updesh Singh Sachdeva
  • Pankaj Malhotra
  • Subhash Varma
Original Article

Abstract

Chronic myelogenous leukemia (CML) is a rare disease in children, accounting for approximately 3% of leukemias in children and adolescents, with an annual incidence of 1 case per million children in western countries. This study was conducted, at PGIMER, Chandigarh. Ninety eight patients, 48 in children and adolescents group, and 50 in adult group were included in the study. Their hematological profiles along with the bone marrow findings were analyzed. The diagnosis of CML was confirmed by cytogenetics and/or molecular analysis. The complete hematological response (CHR) was analyzed at 3 months and cytogentic response (CgR) at 12 months after starting imatinib therapy. Compared to adults, pediatric and adolescent patients were more symptomatic at presentation (93.5 vs. 75%). Among symptomatic patients, massive splenomegaly (>10 cm), higher total leucocyte and platelet counts were seen more frequently in pediatric patients. The most common transcript in both groups was e14a2. The distribution of pediatric and adolescent cases in Sokal, Hasford and EUTOS score, showed only statistically significant difference for low risk Sokal group, which had more patients in pediatric group. Compared to adults, pediatric and adolescent patients had similar CHR rate (91.3 vs. 92%), but showed lesser major CgR rate (90.9 vs. 95.5%) however, this was not statistically significant.

Keywords

Chronic myelogenous leukemia Pediatric Adolescent Adult 

Notes

Compliance with Ethical Standards

Conflict of interest

There are no conflict of interest to declare.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G et al (2005) Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116:140–143CrossRefPubMedGoogle Scholar
  2. 2.
    Hasan SK, Sazawal S, Kumar B, Chaubey R, Mishra P, Mir R et al (2006) Childhood CML in India: b2a2 transcript is more common than b3a2. Cancer Genet Cytogenet 169:76–77CrossRefPubMedGoogle Scholar
  3. 3.
    Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S et al (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97:1029–1035CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al (eds) SEER cancer statistics review, 1975–2007, National Cancer Institute. Bethesda, MD. http://www.seer.cancer.gov/csr/1975-2007
  5. 5.
    Horner MJ, Ries LAG (2007) Leukemia. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (eds) SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988–2001, patient and tumor characteristics. National Cancer Institute, SEER program, NIH, 07-6215Google Scholar
  6. 6.
    Vardiman JW, Melo JV, Baccarani M, Thiele J (2008) Chronic myelogeneous leukemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) World Health Organization classification of tumours of haemopoietic and lymphoid tissues. IARC Press, Lyon, pp 32–37Google Scholar
  7. 7.
    Anand MS, Varma N, Varma S, Rana KS, Malhotra P (2012) Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India. Indian J Med Res 135:42–48CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sokal JE (1987) Prognosis in chronic myeloid leukaemia: biology of the disease versus treatment. Baillieres Clin Haematol 1:907–929CrossRefPubMedGoogle Scholar
  9. 9.
    Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90:850–858CrossRefPubMedGoogle Scholar
  10. 10.
    Hasford J, Baccarani M, Hoffman V, Guilhot J, Saussele S, Rosti G et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118:686–692CrossRefPubMedGoogle Scholar
  11. 11.
    National Comprehensive Cancer Network (2012). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 3. 2013. http://www.nccn.org
  12. 12.
    Hehlman R, Hochhaus S, Baccarani M (2007) European Leukemia Net. Chronic myeloid leukemia. Lancet 370:342–350CrossRefGoogle Scholar
  13. 13.
    Paz-J-Miño C, Burgos R, Morillo SA, Santos JC, Fiallo BF, Leone PE (2002) BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America. Cancer Genet Cytogenet 132:65–67CrossRefGoogle Scholar
  14. 14.
    de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrão AC, Bentes IR et al (2005) Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res 4:803–811PubMedGoogle Scholar
  15. 15.
    Suryanarayan K, Hunger SP, Kohler S et al (1991) Consistent involvement of bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood 77:324–330PubMedGoogle Scholar
  16. 16.
    Mondal BC, Bandyopadhyay A, Majumdar S, Mukhopadhyay A, Chandra S, Chaudhuri U et al (2006) Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol 81:845–849CrossRefPubMedGoogle Scholar
  17. 17.
    Andolina JR, Neudorf SM, Corey SJ (2012) How I treat childhood CML. Blood 119:1821–1830CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Suttorp M, Millot F (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematol Am Soc Hematol Educ Program 2010:368–376Google Scholar
  19. 19.
    Lakshmaiah KC, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM et al (2012) Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma 53:2430–2433CrossRefPubMedGoogle Scholar
  20. 20.
    Kantarjian H, O’Brien S, Jabbour E (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single institution historical experience. Blood 119:1981–1987CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Suttorp M, Glauche I, Salas DG, Tauer JT, Nowasz C, Thiede C (2013) Scoring systems for predicting outcome of chronic myeloid leukemia in adults are poorly informative in pediatric patients treated with imatinib. 55th ASH, New Orleans, Dec 7–10, 2013: abstract no. 2725Google Scholar
  22. 22.
    Bansal D, Shava U, Varma N, Trehan A, Marwaha RK (2012) Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 59:481–484CrossRefPubMedGoogle Scholar
  23. 23.
    Mahon FX, Rea D, Guilhot F et al (2009) Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood 114:859 (ASH Annual Meeting Abstract) Google Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2017

Authors and Affiliations

  • Anita Tahlan
    • 1
  • Neelam Varma
    • 1
    Email author
  • Shano Naseem
    • 1
  • Deepak Bansal
    • 2
  • Jogeshwar Binota
    • 1
  • Anil Sood
    • 1
  • Man Updesh Singh Sachdeva
    • 1
  • Pankaj Malhotra
    • 3
  • Subhash Varma
    • 3
  1. 1.Department of HematologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Department of PediatricsPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  3. 3.Department of Internal MedicinePostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations